Arovella presents at ISCT Dublin
Arovella Therapeutics Ltd (ASX: ALA), a company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform to treat blood and solid cancers, is pleased to announce that today it will be presenting a poster describing its CAR-iNKT cell therapy targeting CLDN18.2-positive cancers at the International Society for Cell and Gene Therapy ISCT 2026 Scientific Annual Meeting in Dublin. The ISCT 2026 is the world’s largest cell and gene therapy (CGT) translation conference, bringing together scientific innovators, clinicians, industry leaders, lab professionals, and regulators to advance translational impact across the CGT sector.
The poster, titled Allogeneic CAR-iNKT cell therapy targeting CLDN18.2-positive gastric and pancreatic cancers, describes in greater detail the data released in Arovella’s announcement on 1 April 2026, CLDN18.2 CAR iNKT Cell Preclinical Data Update. Excitingly, the lead author on the poster, Arovella scientist Dr Clinton Heinze, was also invited to present the poster as an Elevator Pitch oral presentation.
Arovella’s Acting Chief Executive Officer, Dr Nicole Van Der Weerden, commented: “We are delighted to have presented our CLDN18.2-CAR-iNKT cell data at ISCT 2026. The data highlights our progress toward developing a CAR-iNKT cell therapy product for solid tumours such as gastric and pancreatic cancer, which is based on our novel CAR-iNKT cell platform. The data demonstrate that CLDN18.2-targeting CAR-iNKT cells potently eliminate CLDN18.2-positive gastric and pancreatic tumour cells. This cytotoxic activity is further enhanced by incorporating Arovella’s cytokine armouring technology, IL-12-TM, which is designed to improve cell persistence and long-term anti-tumour activity. This complements the work we are doing with our lead candidate, ALA-101, an allogeneic “off-the-shelf” cell therapy for the treatment of CD19+ lymphomas and leukaemias, which is due to commence phase 1 clinical testing in Q3 2026.”
A recent video explanation of the data can be viewed here.
A copy of the poster is attached to this release and is available on our website at https://www.arovella.com